Category Archives: Prescribing Newsletter

Quinine – QT prolongation risk & interactions

Despite repeated warnings about an unfavourable balance between risks and benefits, prescribing of quinine salts in NECS stakeholder CCGs has remained remarkably constant in recent years. The MHRA have issued a reminder about the potential for quinine to effect the QT interval,  along with updated information about interactions – particularly with anticonvulsant drugs. Advice for healthcare professionals: be Continue Reading »


NHS England & NHS Clinical Commissioners have published a quick reference guide (QRG) to Conditions for which over the counter items should not routinely be prescribed in primary care. The OTC QRG sets out the reasons for recommending that certain treatments of limited clinical effectiveness, or used for conditions that are either self-limiting or suitable for self-care, should not be routinely prescribed in primary care Continue Reading »

Ulipristal for uterine fibroids – safety update

In February 2018, the European Medicine Agency Pharmacovigilance Risk Assessment Committee (PRAC) issued temporary recommendations that no new patients should be started on Esmya (ulipristal acetate), following reports of serious injury. The PRAC has completed its review of Esmya. The Committee has now concluded that new patients can start treatment in line with the above recommendations to minimise the risk Continue Reading »

National Medication Safety Dashboard

Following recommendations in the report of the Short Life Working Group on reducing medication-related harm, the Department of Health & Social Care Medicines Safety Programme has developed an open-access Medication Safety Dashboard with a series of preliminary prescribing indicators. A more granular & detailed version of the Medication Safety Dashboard is available via EPACT2. The aim of the indicators is to: Continue Reading »

AHSN Atrial Fibrillation Card Deck_2018 Refresh

The Academic Health Science Network for the North East & North Cumbria have refreshed the Anticoagulant Treatment in Atrial Fibrillation Card Deck distributed to GPs across the region in 2017. The refreshed Card Deck, produced jointly with Northern England Clinical Networks and endorsed by the Atrial Fibrillation Association and the Stroke Association, has been designed to help GPs manage AF more effectively. The Continue Reading »